12 completed, 5 recruiting, 3 unknown, 2 not yet recruiting. 15 Phase 2, 4 Phase 3, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Refractory Chronic Cough: new trials by email Literature Review of Refractory Chronic Cough trials Research Report on Refractory Chronic Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough Morphine Sulphate, Morphine Sulphate + Cough Control Therapy, Pregabalin - Cough, Refractory Chronic Cough | Phase 4 | Not yet recruiting | McMaster University | 124 | 2026-09-30 | 2026-10-19 |
| Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough BCS+inactive, BCS+active - Chronic Cough (CC), Refractory Chronic Cough | Phase 2 | Recruiting | University of Montana | 135 | 2026-08-13 | 2026-08-18 |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Recruiting | Trevi Therapeutics | 100 | 2026-06-22 | 2026-10-13 |
| A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). HW091077, Matching placebo to HW091077 - Refractory Chronic Cough | Phase 2 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 180 | 2026-05-01 | 2026-03-19 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension BLU-5937, Placebo - Refractory Chronic Cough | Phase 3 | Recruiting | GlaxoSmithKline | 75 | 2025-11-21 | 2026-06-16 |
| Cough Management Wellness App for Refractory or Unexplained Chronic Cough Cough Management, CoughMonitor Suite - Refractory Chronic Cough, Unexplained Chronic Cough | Not applicable | Recruiting | Hyfe Inc | 20 | 2025-03-27 | 2025-09-11 |
| Group Telehealth Behavioral Cough Suppression Therapy Behavioral Treatment - Refractory Chronic Cough | Early Phase 1 | Unknown | University of Montana | 60 | 2024-03-22 | 2024-11-27 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 97 | 2023-03-09 | 2026-01-21 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Active not recruiting | Bellus Health Inc. - a GSK company | 997 | 2022-12-05 | 2026-07-14 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Completed | Bellus Health Inc. - a GSK company | 957 | 2022-10-25 | 2026-07-14 |
| Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI) - Refractory Chronic Cough | Phase 1 | Completed | Nocion Therapeutics | 24 | 2022-02-07 | 2023-03-30 |
| Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG - Refractory Chronic Cough | Phase 2 | Recruiting | Mayo Clinic | 50 | 2021-11-01 | 2026-01-21 |
| COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database questionnaires - Refractory Chronic Cough | Terminated | University Hospital, Toulouse | 178 | 2021-06-22 | 2026-04-14 | |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 310 | 2020-12-07 | 2021-12-13 |
| Indomethacin for Refractory Chronic Cough indomethacin, Placebo, Omeprazole - Refractory Chronic Cough | Phase 3 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 84 | 2018-10-22 | 2018-11-26 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough 5 mg Serlopitant Tablets, Matching Placebo Tablets - Refractory Chronic Cough | Phase 2 | Completed | Vyne Therapeutics Inc. | 185 | 2017-10-03 | 2021-05-20 |
| An 8-Week Refractory Chronic Cough Study (MK-7264-021) Gefapixant, Placebo (for gefapixant) - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 24 | 2015-12-17 | 2019-11-25 |
| A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Gefapixant, Placebo (for gefapixant) - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 253 | 2015-12-15 | 2020-06-30 |
Showing 20 of 24. Sign in to see all of them.
Chronic Cough (24) · Cough (7) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Signs and Symptoms, Respiratory (2) · cough hypersensitivity syndrome (2) · Asthma (1) · Gastroesophageal Reflux (1) · upper airway cough syndrome (1)
Pathological Conditions, Signs and Symptoms (24) · Signs and Symptoms (24) · Respiration Disorders (22) · Respiratory Tract Diseases (22) · Signs and Symptoms, Respiratory (22) · Cough (17) · Bronchial Diseases (1) · Deglutition Disorders (1) · Digestive System Diseases (1) · Esophageal Diseases (1) · Esophageal Motility Disorders (1) · Gastrointestinal Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
Gefapixant (5) · BLU-5937 (4) · Nalbuphine (2) · Amitriptyline (1) · Behavior Therapy (1) · Duloxetine Hydrochloride (1) · Indomethacin (1) · Morphine (1) · Omeprazole (1) · Pregabalin (1) · Surveys and Questionnaires (1) · serlopitant (1)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Bellus Health Inc. - a GSK company (3) · Trevi Therapeutics (2) · University of Montana (2) · Beijing Tide Pharmaceutical Co., Ltd (1) · GlaxoSmithKline (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (1) · Hyfe Inc (1) · Mayo Clinic (1) · McMaster University (1) · Nocion Therapeutics (1) · Patara Pharma (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · University Hospital, Toulouse (1)
United States (10) · United Kingdom (7) · Canada (6) · China (4) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · India (2) · Netherlands (2) · Poland (2) · Argentina (1) · Australia (1) · Belgium (1) · Colombia (1)
Amanda Gillespie, PhD (1) · Christopher Silber, MD (1) · Imran Satia, MD PhD (1) · Jacky Smith (1) · Laurie J Slovarp, PhD (1) · Vivek N Iyer, MD (1)
PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 34697975, PMID 35614875, PMID 36348054, PMID 39706278, PMID 40043302, PMID 41046288
2015 (4), 2017 (1)